Proton Pump Inhibitors and Biomarkers of Haemostasis in Postmenopausal Women: The Buffalo OsteoPerio Study

Examine the association between proton pump inhibitor (PPI) use and plasma levels of four biomarkers of haemostasis: fibrinogen, von Willebrand factor (vWF), high-sensitivity CRP (hs-CRP) and plasminogen activator inhibitor-1 (PAI-1) in postmenopausal women.

We conducted a cross-sectional analysis on 200 women in the Buffalo Osteoporosis and Periodontitis study Year 17 visit. PPI use was assessed using medication inventories, and biomarkers were measured using frozen plasma samples. Linear regression was used to estimate mean differences for each biomarker according to PPI use (yes/no) and duration (≤ 1 year, > 1 year). Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for having a high versus low level of each biomarker. Models were adjusted for major cardiovascular risk factors to account for potential confounding.

PPI users had non-statistically significant higher levels of vWF (mean difference = 52.9 mIU/mL, p = 0.38) and log hs-CRP (mean difference = 0.1 mg/L, p = 0.5) compared to non-users. PPI users for > 1 year had non-statistically significant higher odds of having a high level of vWF (OR = 1.08, 95% CI: 0.51-2.31) and hs-CRP (OR = 1.16, 95% CI: 0.58-2.33) compared to non-users.

There was no significant association between PPI use and measured plasma haemostatic markers.